Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Investors

Fresenius Investment Highlights

Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management

"2019 was a good year for Fresenius. A year of challenges, but also of many successes. We have treated even more patients, launched new products, and increased our sales to more than 35 billion euros. We made the planned, significant investments in our future growth, yet have still achieved a slight increase in earnings. Fresenius is well positioned to stay successful into the future. We can look ahead with confidence, and confirm our ambitious medium-term targets."

(Stephan Sturm, Chairman of the Management Board)

LATEST

March

18

March 18, 2020 | Bad Homburg, Germany

Annual Report 2019

Consolidated Financial Statements and Management Report (IFRS)

Online Annual Report Import (ICS) Financial Statements 2019 (HGB) (PDF) Annual Report 2019 (IFRS) (PDF)

LATEST

News

Fresenius successfully places bonds with a volume of 750 million euros

Fresenius today successfully places bonds with a volume of €750 million.
March 31, 2020Fresenius
Fresenius postpones 2020 Annual General Meeting

March 30, 2020Fresenius

Fresenius takes comprehensive measures to combat COVID 19 pandemic in Germany

March 27, 2020Fresenius Helios
Brief News
Fresenius Kabi resumes normal operations in China

With virtually all of Fresenius Kabi’s manufacturing staff in China returning to work post government-imposed COVID-19 quarantine restrictions, the company is ramping-up production back to normal levels. With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China. Even though Fresenius Kabi faced challenges due to the COVID-19 pandemic and the quarantine measures, there was no major interruption of production. Thus, the company can supply the Chinese population with essential pharmaceuticals and medical devices.

March 24, 2020Fresenius Kabi

Fresenius Helios makes significant contribution to combating COVID-19 crisis in Spain

March 20, 2020Fresenius Helios
Brief News
Fresenius annual report 2019 online available

Our Annual Report 2019 is now available as a full-content PDF download and as an online short-version with the highlights. Annual Report (PDF) Online short-version

March 18, 2020Fresenius

Brief News
Fresenius subsidiary Curalie acquires Digitale Gesundheitsgruppe

Curalie, a subsidiary of Fresenius, has acquired Digitale Gesundheitsgruppe (DGG), one of its main competitors in Germany. Curalie and DGG both develop digital healthcare offerings to help patients with chronic illnesses. DGG targets family and specialist physicians with its “TeLiPro” telemedicine platform, while Curalie develops digital solutions for rehabilitation and aftercare. Combining the two companies creates the first provider that in all sectors of healthcare can digitally support patients during outpatient and inpatient care and through to aftercare.

March 18, 2020Fresenius
Brief News
Fresenius Kabi launches IV solution in the U.S.

Sodium Chloride 3% is the newest addition to the company’s IV solution portfolio.

March 16, 2020Fresenius Kabi

Fresenius reports 16th consecutive record year - Significant investments into growth – Healthy growth for 2020 expected – Medium-term growth targets confirmed

February 20, 2020Fresenius
Brief News
Fresenius Kabi and Vifor Pharma create joint venture in China for i.v. iron portfolio

Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.

February 20, 2020Fresenius Kabi

Fresenius Helios acquires first hospital in Bogotá, continuing expansion in Colombia’s private hospital market

February 19, 2020Fresenius Helios
Brief News
Fresenius Kabi diversifies U.S. product portfolio

With the launch of a Glucagon Emergency Kit, Fresenius Kabi offers an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes. This is the company’s first pharma product sold and used primarily outside hospitals in the U.S.

February 05, 2020Fresenius Kabi

Brief News
Fresenius Kabi enters into joint venture to advance new cell and gene therapies

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No other financial terms were disclosed.

January 21, 2020Fresenius Kabi
Brief News
Fresenius Helios trains doctors in antibiotics management

Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

January 16, 2020Fresenius Helios

Fresenius successfully places bonds with a volume of 750 million euros

January 07, 2020Fresenius
Fresenius Helios acquires leading private hospital in Colombia

December 23, 2019Fresenius Helios

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.

December 20, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.

December 19, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Ertapenem, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

December 11, 2019Fresenius Kabi
Brief News
Fresenius Helios awards new innovation prize

Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

December 10, 2019Fresenius Helios

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Fosaprepitant, an antiemetic, expands the company's large sterile injectable portfolio in oncology.

November 13, 2019Fresenius Kabi
Brief News
Fresenius Vamed completes main university hospital building in Lübeck

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Lübeck. Following the opening in August of the new main building at the UKSH’s other location, in Kiel, the modernization of Germany’s second-largest university hospital is now largely complete. In addition to the new construction and the comprehensive renovation of the two university hospital locations, the project includes their technical management through 2044. With a total volume of €1.7 billion, the UKSH modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

November 12, 2019Fresenius Vamed

Brief News
Fresenius Vamed wins awards for spa and wellness facilities

VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2019” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Spa Villas, St. Martins Therme & Lodge, Therme Laa Hotel & Spa and la pura women’s health resort – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria.

November 05, 2019Fresenius Vamed
Fresenius Helios acquires medical diagnostics provider in Colombia

November 04, 2019Fresenius Helios

Fresenius confirms guidance after solid third quarter

October 29, 2019Fresenius
Brief News
Fresenius Kabi launches new Heparin Sodium in prefilled syringe in the U.S.

A new presentation of Fresenius Kabi Heparin is now available in the company’s Simplist^® ready-to-administer prefilled syringe, expanding the company's Heparin portfolio.

October 25, 2019Fresenius Kabi

Brief News
Fresenius Kabi expands plant in Brazil

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

October 23, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches Fulvestrant in prefilled syringes in the U.S.

Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

October 07, 2019Fresenius Kabi

Brief News
Fresenius Helios develops system to measure patient safety

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

September 18, 2019Fresenius Helios
Brief News
Fresenius Kabi opens research and development center for biosimilars in Switzerland

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

September 18, 2019Fresenius Kabi

Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

I am a private investor I am an institutional investor

Title *

First name * Please enter your first name.

Last name * Please enter your last name.

Company * Please enter your company.

Department * Please enter your department.

Job function *

Please enter your function.

Street / Number * Please enter your street.

Postal Code / City * Please enter your postal code and city.

Country *

E-mail * Please enter your e-mail address.

Telephone number

All fields marked with * are required.

Please send me via email

Fresenius Brief News German English

Fresenius Investor News German English

Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us